Univ Of Missouri Health Care
- Type
- Teaching hospital
- Where
- COLUMBIA, MO
- Medicare CCN
- 260141
- Received
- $10,005,286 in 646 records, 2022 ($6,448,646 general, $3,556,640 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 226 | $6,448,646 |
| 2022 | Research payment | 420 | $3,556,640 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 100 | $5,792,747 |
| Research payment | 420 | $3,556,640 |
| Grant | 16 | $273,398 |
| Consulting Fee | 13 | $204,639 |
| Space rental or facility fees (teaching hospital only) | 78 | $68,349 |
| Education | 2 | $55,000 |
| Debt forgiveness | 5 | $22,653 |
| Royalty or License | 2 | $20,365 |
| Long term medical supply or device loan | 4 | $9,050 |
| Charitable Contribution | 6 | $2,441 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,681 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,283 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $6,217 | Research payment | In-kind items and services | TEZSPIRE Biological, Respiratory | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,202 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | Stryker Corporation | $4,506 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,125 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,852 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participa | 2022 |
| 2022-12-31 | ABBVIE INC. | $2,065 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,459 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participa | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $989 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | Stryker Corporation | $888 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | AstraZeneca UK Limited | $684 | Research payment | In-kind items and services | A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti | 2022 | |
| 2022-12-31 | UROGEN PHARMA, INC. | $392 | Research payment | In-kind items and services | UROGEN PHARMA BL011 | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $23 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex MK-8616 for the Reve | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $23 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex MK-8616 for the Reve | 2022 |
| 2022-12-31 | AstraZeneca UK Limited | $4 | Research payment | In-kind items and services | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclon | 2022 | |
| 2022-12-28 | Regeneron Pharmaceuticals, Inc. | $1,310 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2022 |
| 2022-12-23 | ModernaTX, Inc. | $11,558 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-12-23 | ViiV Healthcare Company | $4,528 | Research payment | Cash or cash equivalent | A PHASE 4, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY EVALUATING IMPLEMENTA | 2022 | |
| 2022-12-22 | UROGEN PHARMA, INC. | $14,813 | Research payment | Cash or cash equivalent | BL011 | 2022 | |
| 2022-12-22 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-12-21 | ModernaTX, Inc. | $5,022 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-12-21 | ROCHE MOLECULAR SYSTEMS, INC. | $5,000 | Consulting Fee | Cash or cash equivalent | Device | 2022 | |
| 2022-12-21 | BioMarin Pharmaceutical Inc. | $98 | Research payment | Cash or cash equivalent | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | 2022 | |
| 2022-12-19 | Advanced Accelerator Applications | $348,331 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-12-19 | Advanced Accelerator Applications | $266,547 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-12-19 | Advanced Accelerator Applications | $245,836 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-12-19 | Advanced Accelerator Applications | $235,237 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-12-19 | Advanced Accelerator Applications | $158,246 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-12-16 | Baxter Healthcare | $4,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Renal - HD Device, Renal | 2022 | |
| 2022-12-16 | Baxter Healthcare | $4,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Renal - HD Device, Renal | 2022 | |
| 2022-12-16 | Innovation Technologies Inc | $1,160 | Research payment | Cash or cash equivalent | IRRISEPT Device, JET LAVAGE DEVICE WITH CHG | PROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR | 2022 |
| 2022-12-16 | CSL Behring | $684 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-12-16 | ModernaTX, Inc. | $619 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-12-16 | PFIZER INC. | $416 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-12-15 | Arthrex, Inc. | $4,863 | Research payment | Cash or cash equivalent | DISTAL EXTREMITIES INSTRUMENTS TRAUMA KNEE TRAUMA Device, DISTAL EXTREMITIES - INSTRUMENTS - TRAUMA - KNEE TRAUMA | Biomechanical Comparison of Nitinol Compression Staples Versus Fully Threaded Lag Screws for Talonav | 2022 |
| 2022-12-15 | Medtronic, Inc. | $3,995 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-15 | Medtronic, Inc. | $1,089 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-15 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-12-15 | Medtronic, Inc. | $68 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-15 | Medtronic, Inc. | $68 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-14 | LivaNova USA, Inc. | $301 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-12-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-12-12 | Advanced Accelerator Applications | $58,066 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-12-12 | Advanced Accelerator Applications | $3,969 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-12-10 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-12-09 | ModernaTX, Inc. | $14,970 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-12-09 | ModernaTX, Inc. | $1,740 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-12-08 | EMD Serono, Inc. | $839 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-12-07 | Ortho-Clinical Diagnostics, Inc. | $10,419 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VITROS XT 3400 Chemistry System Device, DIAGNOSTICS | 2022 | |
| 2022-12-07 | Ortho-Clinical Diagnostics, Inc. | $9,190 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VITROS XT 3400 Chemistry System Device, DIAGNOSTICS | 2022 | |
| 2022-12-07 | Ortho-Clinical Diagnostics, Inc. | $2,760 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VITROS 3600 Immunodiagnostic System Device, DIAGNOSTICS | 2022 | |
| 2022-12-07 | ModernaTX, Inc. | $2,377 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-12-06 | Becton, Dickinson and Company | $4,734 | Research payment | In-kind items and services | ISS 71856057 | 2022 | |
| 2022-12-05 | AXOGEN | $10,360 | Research payment | Cash or cash equivalent | AVANCE NERVE GRAFT | Registry of Avance Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction (RANGER) | 2022 |
| 2022-12-05 | GENZYME CORPORATION | $5,250 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2022 | |
| 2022-12-05 | GENZYME CORPORATION | $925 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2022 | |
| 2022-12-05 | GENZYME CORPORATION | $50 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2022 | |
| 2022-12-01 | LivaNova USA, Inc. | $1,932 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-12-01 | ModernaTX, Inc. | $1,786 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-12-01 | Regeneron Pharmaceuticals, Inc. | $1,108 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2022 |
| 2022-12-01 | Regeneron Pharmaceuticals, Inc. | $988 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2022 |
| 2022-12-01 | Regeneron Pharmaceuticals, Inc. | $672 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2022 |
| 2022-12-01 | Regeneron Pharmaceuticals, Inc. | $642 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2022 |
| 2022-11-30 | Tandem Diabetes Care, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2022 | |
| 2022-11-30 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-11-29 | Takeda Pharmaceuticals U.S.A., Inc. | $530 | Research payment | Cash or cash equivalent | NATPARA (PARATHYROID HORMONE) Drug, INTERNAL MEDICINE | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2022 |
| 2022-11-28 | Novo Nordisk AS | $700 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4416 | 2022 |
| 2022-11-25 | ModernaTX, Inc. | $9,463 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-25 | Medical Device Business Services, Inc. | $1,047 | Research payment | Cash or cash equivalent | DePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na | 2022 | |
| 2022-11-25 | Medical Device Business Services, Inc. | $1,047 | Research payment | Cash or cash equivalent | DePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na | 2022 | |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $7,000 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,878 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,878 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,878 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,878 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,878 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,637 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,500 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-23 | ModernaTX, Inc. | $24,929 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 COVID-19 Vaccine in Healthy Children Between 6 Mo | 2022 | |
| 2022-11-23 | EMD Serono, Inc. | $12,206 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-11-23 | ModernaTX, Inc. | $5,000 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-23 | ModernaTX, Inc. | $3,930 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-23 | Stryker Corporation | $3,480 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY | 2022 |
| 2022-11-23 | ModernaTX, Inc. | $3,144 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-23 | ModernaTX, Inc. | $3,144 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-23 | EMD Serono, Inc. | $1,838 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-11-23 | ModernaTX, Inc. | $327 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-23 | UROGEN PHARMA, INC. | $76 | Research payment | In-kind items and services | UROGEN PHARMA BL011 | 2022 | |
| 2022-11-23 | UROGEN PHARMA, INC. | $71 | Research payment | In-kind items and services | UROGEN PHARMA BL011 | 2022 | |
| 2022-11-23 | ModernaTX, Inc. | $52 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-23 | ModernaTX, Inc. | $19 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-22 | LivaNova USA, Inc. | $3,419 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-11-22 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,741 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-11-22 | Innovation Technologies Inc | $1,160 | Research payment | Cash or cash equivalent | IRRISEPT Device, JET LAVAGE DEVICE WITH CHG | PROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR | 2022 |
| 2022-11-22 | ROCHE MOLECULAR SYSTEMS, INC. | $900 | Consulting Fee | Cash or cash equivalent | Device | 2022 | |
| 2022-11-19 | Linde Gas & Equipment Inc. | $733 | Space rental or facility fees (teaching hospital only) | In-kind items and services | MM NO800NI-AQ Device, Respiratory | 2022 | |
| 2022-11-18 | Penumbra, Inc. | $949 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2022 |
| 2022-11-17 | Medical Device Business Services, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-11-17 | UROGEN PHARMA, INC. | $230 | Research payment | In-kind items and services | UROGEN PHARMA BL011 | 2022 | |
| 2022-11-17 | UROGEN PHARMA, INC. | $214 | Research payment | In-kind items and services | UROGEN PHARMA BL011 | 2022 | |
| 2022-11-16 | bioMerieux Inc | $1,304 | Research payment | Cash or cash equivalent | Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients and Clinical and Laboratory Featur | 2022 | |
| 2022-11-16 | ModernaTX, Inc. | $696 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-15 | Medtronic, Inc. | $10,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-11-14 | ModernaTX, Inc. | $23,455 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-14 | ModernaTX, Inc. | $10,322 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-14 | ModernaTX, Inc. | $6,877 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-14 | Regeneron Pharmaceuticals, Inc. | $6,684 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN CAT-ALLERGIC PATIENTS WITH ALLERGIC RHINITIS WHO LIVE WITH A CAT | 2022 | |
| 2022-11-11 | PFIZER INC. | $442 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-11-10 | Arthrex, Inc. | $22,797 | Research payment | Cash or cash equivalent | Pilot Study: Safety of IOBP for MODIC | 2022 | |
| 2022-11-10 | Optinose US, Inc. | $2,189 | Research payment | Cash or cash equivalent | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2022 | |
| 2022-11-10 | ALK-Abello, Inc | $1,744 | Research payment | Cash or cash equivalent | Odactra Drug, Allergy and Immunology | MT-12 | 2022 |
| 2022-11-09 | ModernaTX, Inc. | $543 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-11-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2022 | |
| 2022-11-08 | Siemens Medical Solutions USA, Inc. | $40,000 | Research payment | Cash or cash equivalent | ADVIA Centaur XP Analyzer Device, DX - Diagnostics incl. all products and services | Cov2Ag sample collection | 2022 |
| 2022-11-08 | Siemens Medical Solutions USA, Inc. | $6,869 | Research payment | Cash or cash equivalent | Artis icono floor Device, AT - Fixed interventional x-ray/angiography fluoroscopy | MU Hirai icono dose reduction AT Clinical | 2022 |
| 2022-11-07 | Medical Device Business Services, Inc. | $1,794 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-11-07 | Medical Device Business Services, Inc. | $1,794 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-11-07 | Medical Device Business Services, Inc. | $892 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-11-07 | Medical Device Business Services, Inc. | $892 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-11-07 | Ethicon Endo-Surgery Inc. | $537 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Prospective, Single-Arm, Multi-Center Study of the ECHELON EndopathTM Staple Line Reinforcement Device in Bariatric an | 2022 |
| 2022-11-07 | UROGEN PHARMA, INC. | $153 | Research payment | In-kind items and services | UROGEN PHARMA BL011 | 2022 | |
| 2022-11-05 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-11-03 | ABBVIE INC. | $930 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pa | 2022 |
| 2022-11-02 | LivaNova USA, Inc. | $2,069 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-11-01 | UROGEN PHARMA, INC. | $16,600 | Research payment | Cash or cash equivalent | BL011 | 2022 | |
| 2022-10-31 | UROGEN PHARMA, INC. | $142 | Research payment | In-kind items and services | UROGEN PHARMA BL011 | 2022 | |
| 2022-10-28 | Medtronic, Inc. | $89,331 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | Investigator Sponsored Research | 2022 |
| 2022-10-28 | ModernaTX, Inc. | $8,217 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-10-28 | ModernaTX, Inc. | $339 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-10-27 | Ipsen Pharma SAS | $10,480 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2022 |
| 2022-10-27 | EMD Serono, Inc. | $1,878 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemothera | 2022 | |
| 2022-10-27 | Ipsen Pharma SAS | $1,500 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2022 |
| 2022-10-26 | LivaNova USA, Inc. | $49,884 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-10-26 | ModernaTX, Inc. | $8,378 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-10-26 | Ipsen Pharma SAS | $2,073 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2022 |
| 2022-10-26 | Ipsen Pharma SAS | $1,041 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2022 |
| 2022-10-26 | Ipsen Pharma SAS | $958 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2022 |
| 2022-10-25 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,741 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-10-25 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,741 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-10-25 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,741 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-10-25 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,417 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-10-25 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,417 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-10-24 | Merck Sharp & Dohme LLC | $1,965 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participa | 2022 |
| 2022-10-24 | Novo Nordisk AS | $1,310 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4416 | 2022 |
| 2022-10-22 | Grifols Therapeutics LLC | $6,726 | Research payment | Cash or cash equivalent | Albutein Biological, Critical Care Medicine | Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Asci | 2022 |
| 2022-10-21 | BioMarin Pharmaceutical Inc. | $7,061 | Research payment | Cash or cash equivalent | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | 2022 | |
| 2022-10-20 | Novocure Inc. | $1,350 | Research payment | Cash or cash equivalent | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2022 | |
| 2022-10-20 | Regeneron Pharmaceuticals, Inc. | $662 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2022 |
| 2022-10-19 | Innovation Technologies Inc | $5,840 | Research payment | Cash or cash equivalent | IRRISEPT Device, JET LAVAGE DEVICE WITH CHG | PROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR | 2022 |
| 2022-10-19 | Merz Pharmaceuticals, LLC | $4,028 | Research payment | Cash or cash equivalent | Xeomin Biological, Musculoskeletal | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of N | 2022 |
| 2022-10-19 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2022 | |
| 2022-10-18 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pa | 2022 |
| 2022-10-18 | ABBVIE INC. | $1,500 | Grant | Cash or cash equivalent | VUITY Drug, OPHTHALMOLOGY | 2022 | |
| 2022-10-18 | Regeneron Pharmaceuticals, Inc. | $1,455 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION T | 2022 |
| 2022-10-17 | Medical Device Business Services, Inc. | $2,041 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-10-17 | Medical Device Business Services, Inc. | $2,041 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-10-17 | PFIZER INC. | $492 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-10-14 | ModernaTX, Inc. | $3,930 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-10-14 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY | 2022 |
| 2022-10-13 | MicroVention, Inc. | $500 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-10-12 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2022 | |
| 2022-10-10 | Advanced Accelerator Applications | $209,757 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-10-10 | Advanced Accelerator Applications | $209,757 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-10-10 | Advanced Accelerator Applications | $209,132 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-10-10 | Advanced Accelerator Applications | $61,722 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-10-07 | ModernaTX, Inc. | $54,578 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-10-07 | Penumbra, Inc. | $425 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2022 |
| 2022-10-07 | ModernaTX, Inc. | $262 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-10-05 | ModernaTX, Inc. | $36,394 | Research payment | Cash or cash equivalent | An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Varian | 2022 | |
| 2022-10-05 | Veryan Medical Incorporated | $26,979 | Research payment | Cash or cash equivalent | BioMimics 3D Vascular Stent System Device, Vascular Stent | A prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p | 2022 |
| 2022-10-05 | Veryan Medical Incorporated | $14,265 | Research payment | Cash or cash equivalent | BioMimics 3D Vascular Stent System Device, Vascular Stent | A prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p | 2022 |
| 2022-10-05 | Veryan Medical Incorporated | $6,847 | Research payment | Cash or cash equivalent | BioMimics 3D Vascular Stent System Device, Vascular Stent | A prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p | 2022 |
| 2022-10-05 | Veryan Medical Incorporated | $1,633 | Research payment | Cash or cash equivalent | BioMimics 3D Vascular Stent System Device, Vascular Stent | A prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p | 2022 |
| 2022-10-03 | ModernaTX, Inc. | $46,825 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-09-30 | Medical Device Business Services, Inc. | $8,500 | Research payment | Cash or cash equivalent | DePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na | 2022 | |
| 2022-09-30 | Exelixis Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cabometyx Drug, Oncology | 2022 | |
| 2022-09-29 | Medical Device Business Services, Inc. | $654 | Research payment | Cash or cash equivalent | DePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na | 2022 | |
| 2022-09-28 | ModernaTX, Inc. | $1,843 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-09-28 | BioMarin Pharmaceutical Inc. | $1,492 | Research payment | Cash or cash equivalent | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | 2022 | |
| 2022-09-28 | LivaNova USA, Inc. | $1,146 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-09-28 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2022 | |
| 2022-09-28 | BioMarin Pharmaceutical Inc. | $196 | Research payment | Cash or cash equivalent | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | 2022 | |
| 2022-09-27 | Advanced Accelerator Applications | $43,804 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-09-27 | Advanced Accelerator Applications | $37,806 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-09-27 | Advanced Accelerator Applications | $24,332 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2022 | |
| 2022-09-26 | ModernaTX, Inc. | $1,843 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-09-26 | ModernaTX, Inc. | $1,834 | Research payment | Cash or cash equivalent | Moderna Covid-19 Vaccine Biological, Infections and Infectious Diseases | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled | 2022 |
| 2022-09-26 | Innovation Technologies Inc | $1,111 | Research payment | Cash or cash equivalent | IRRISEPT Device, JET LAVAGE DEVICE WITH CHG | PROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING TEMPORARY EXTERNAL FIXATOR TO ANTIBIOTIC-COATED IM NAIL FOR OPEN TIBIA FR | 2022 |
| 2022-09-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,741 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-09-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,417 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-09-24 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,417 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PRIMARY CARE | A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disinte | 2022 |
| 2022-09-23 | CSL Behring | $794 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-09-23 | CSL Behring | $65 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-09-22 | Synthes GmbH | $6,000 | Grant | In-kind items and services | 2022 | ||
| 2022-09-22 | Medtronic, Inc. | $2,565 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-22 | Medtronic, Inc. | $739 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-22 | Medtronic, Inc. | $739 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-22 | Stryker Corporation | $625 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL | 2022 |
The latest 200 records of 646.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Columbia, MO, county Boone County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Columbia, MO | County Boone County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 128,548 | 188,043 | 6,191,814 |
| Population, 2020 census P1 | 126,254 | 183,610 | 6,154,913 |
| Median age B01002 | 29.5 | 32.7 | 39.0 |
| Under 18 B01001 | 18.7% | 20.1% | 22.3% |
| 65 and over B01001 | 11.6% | 13.5% | 17.9% |
| Households B11001 | 52,564 | 76,562 | 2,508,227 |
| Foreign born B05002 | 8.1% | 6.4% | 4.5% |
| Median household income B19013 | $66,498 | $72,758 | $70,702 |
| Median family income B19113 | $106,412 | $104,323 | $91,360 |
| Per capita income B19301 | $39,340 | $40,954 | $39,695 |
| Poverty rate B17001 | 19.3% | 16.6% | 12.6% |
| Unemployment rate B23025 | 4.0% | 3.8% | 4.0% |
| Civilian labor force B23025 | 70,686 | 102,651 | 3,120,639 |
| Mean commute (minutes) B08013 | 16.4 | 18.7 | 23.5 |
| Bachelor's degree or higher B15003 | 56.7% | 51.5% | 32.4% |
| Housing units B25001 | 56,054 | 81,675 | 2,825,287 |
| Owner-occupied B25003 | 48.7% | 57.7% | 68.1% |
| Renters B25003 | 51.3% | 42.3% | 31.9% |
| Median home value B25077 | $284,600 | $272,800 | $230,300 |
| Median gross rent B25064 | $1,097 | $1,088 | $1,033 |
| White, not Hispanic B03002 | 71.7% | 75.8% | 76.3% |
| Black B03002 | 12.1% | 9.5% | 10.9% |
| Hispanic or Latino B03002 | 4.4% | 4.5% | 5.2% |
| Asian B03002 | 6.3% | 4.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Columbia, MO.
Comments